Global Breast Cancer Academy

Sharing Best Practices to Optimize Patient Care in Europe

Register Now

Overview

In recent years, progress in screening of high-risk populations, identification of actionable molecular targets, and immunotherapy have rapidly transformed the treatment paradigm for patients with breast cancer. Aptitude Health developed the Global Breast Cancer Academy to help physicians bridge the gap between innovation and implementation for patient care.

Register Now

Date and Location

14 November 2023; Virtual Meeting

Meeting Content

View the slides and watch the video of the event.

View Slides Watch Video

Chair

Nadia Harbeck

Nadia Harbeck, MD, PhD

Ludwig-Maximilian University of Munich, Germany

Faculty

Giuseppe Curigliano

Giuseppe Curigliano, MD, PhD

University of Milano, Italy

Sara Tolaney

Sara Tolaney, MD, MPH

Dana Farber Cancer Institute, Boston, MA, USA

Anna Berghoff

Anna Berghoff, MD, PhD

Medical University of Vienna, Austria

Agenda

This interactive virtual meeting with global experts will focus on the treatment of patients with HER2+ breast cancer in Europe.

  • Follow presentations and engage with the faculty in case-based panel discussions on optimal treatment and patient access, and regional challenges across Europe.

 

Time Topic Speaker
16.30 – 16.40 Welcome and meeting overview; introduction to the voting system Nadia Harbeck
Is Everything Well in the Evolving World of HER2+ mBC Treatment?
16.40 – 17.00 Major advances in early lines of treatment for HER2+ mBC Nadia Harbeck
17.00 – 17.20 What are the treatment options after second line? Giuseppe Curigliano
17.20 – 17.35 Overcoming resistance to HER2-directed therapies Sara Tolaney
17.35 – 17.50 Modern treatment approaches for patients with brain metastases Anna Berghoff
17.50 – 18.00 Break  
How Does HER2+ mBC Treatment Look Today and Tomorrow?
18.00 – 18.30

Panel discussion on sequencing strategies: Use the best up front or keep it for later lines?

  • What is the optimal sequencing strategy of HER2-targeted agents in the metastatic setting?
  • What drives the sequencing decisions?
 Nadia Harbeck and all faculty
18.30 – 18.50 Toward a better reality: How real-world challenges shape future clinical studies, including the rise of HER2-low as a new entity in mBC Giuseppe Curigliano
18.50 – 19.20

BC case-based panel discussion

  • Case 1 HER2+ mBC – what do we do after T-DXd?
  • Case 2 HER2+ mBC – what do we do with CNS progression?
  • Discussion – panelists: all faculty
 Nadia Harbeck and all faculty
Elie El-Rassy
Rodrigo Sánchez-Bayona
19.20 – 19.30 Session close Nadia Harbeck

Register Now